Core Scientific (CORZ) Q3 2026 Earnings Call Transcript

Core Scientific's Q3 colocation revenue rose nearly 60% sequentially to $215.4 million, while adjusted EBITDA increased to $133.6 million from $41.1 million and its adjusted EBITDA margin expanded to 57% from 25%. Management expects a double-digit sequential revenue increase in Q4 and is transitioning toward a colocation-focused business, with 1.1 GW contracted across CoreWeave and AMD; the reported $1.2 billion net income primarily reflected a non-cash fair-value gain on warrants. Financing remains a key constraint on development pace: liquidity was $1.7 billion at quarter-end, and management is pursuing project financing for AMD builds.

Analysis

CORZ’s key underwriting variable is no longer whether it can deliver one campus; it is whether it can finance the next wave without giving away too much equity value. The operating ramp supports near-term earnings momentum, but reported EBITDA should not be treated as distributable cash: property-level NOI precedes corporate costs and financing, while straight-line lease accounting can pull revenue forward relative to cash receipts. The non-cash warrant gain also makes GAAP net income a poor read-through to operating performance.

The market may be underpricing the distinction between contracted capacity and development options. CoreWeave’s remaining build is relatively close to billing, but AMD’s 1.9 GW reservation rights are not firm orders; power, permitting, and customer commitment decisions remain gating items. This creates upside optionality, not a bankable base case. If capital is scarce industry-wide, CORZ could gain share by acquiring partially developed assets, but acquisitions would compete with funding already-committed builds for management attention and balance-sheet capacity.

Near term (days to weeks), expect the revenue ramp to support sentiment; the more consequential 1–3 month catalysts are project-bond pricing/terms, remaining CoreWeave commissioning, and Texas permitting/energization milestones. Over 6–18 months, AMD delivery and the conversion of reservation rights—not headline pipeline size—determine whether the business earns a higher multiple. The contrarian risk is that investors capitalize stabilized NOI before financing costs, dilution, and execution slippage are visible. Warrant proceeds bolster liquidity but bring dilution; restricted cash is not equivalent to freely deployable capital.

Key Decisions for Investors

• CORZ: avoid chasing the earnings-step-up; consider a staged long only after project financing is priced on acceptable terms and near-term delivery milestones remain intact. Reassess if bond terms imply materially higher financing costs, or if Texas permits/energization or CoreWeave commissioning slip.
• Track the AMD reservation deadlines as an option-value catalyst, not contracted backlog. Upgrade the long thesis only when AMD converts reservations into commitments and CORZ demonstrates credible power and permitting paths; a missed commitment window or weaker-than-expected project economics falsifies the expansion case.
• Model cash generation separately from adjusted EBITDA: verify lease cash receipts versus straight-line revenue, unrestricted cash after project requirements, and the fully diluted share count around the January warrant exercise. If liquidity depends materially on restricted reserves or repeated equity-linked funding, reduce exposure.
• No clean relative-value short is established by this call alone. RIOT’s announced transaction may validate demand for powered sites, but it does not establish comparable economics or make RIOT a natural hedge for CORZ.